Skip to main content
. 2017 May 18;8(43):75646–75663. doi: 10.18632/oncotarget.17980

Table 2. Emerging therapies for the treatment of musculoskeletal consequences of androgen deprivation therapy.

Agents targeting bone Agents targeting muscle
Chloride Channel Modulators Androgen Receptor Modulators (SARM)
Anti-cathepsin K GH Secretagogues
Anti-Integrins PPAR-beta Modulators
Src inhibitors Anti-Myostatin Antibodies
Androgen Receptor Modulators (SARM) Myostatin Soluble Receptors
GLP2 Anti-Activin II Receptors
Inhibitor of gut serotonin Angiotensin II Blockades
Anti-sclerostin Beta-2 Receptor Agonists
Anti-Dickkopf Anti-IL-6
Modulators of LRPs Pathway
Anti-activin Anti-activin